دورية أكاديمية
Synchronous spectrofluorimetry and chemometric modeling: A synergistic approach for analyzing simeprevir and daclatasvir, with application to pharmacokinetics evaluation.
| العنوان: | Synchronous spectrofluorimetry and chemometric modeling: A synergistic approach for analyzing simeprevir and daclatasvir, with application to pharmacokinetics evaluation. |
|---|---|
| المؤلفون: | Serag A; Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Al-Azhar University, 11751 Nasr City, Cairo, Egypt. Electronic address: Ahmedserag777@azhar.edu.eg., Alnemari RM; Department of Pharmaceutics and Pharmaceutical Technology, College of Pharmacy, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia., Abduljabbar MH; Department of Pharmacology and Toxicology, College of Pharmacy, Taif University, P.O. Box 11099, 21944 Taif, Saudi Arabia., Alosaimi ME; Department of Basic Sciences, College of Medicine, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia., Almalki AH; Department of Pharmaceutical Chemistry, College of Pharmacy, Taif University, P.O. Box 11099, 21944 Taif, Saudi Arabia; Addiction and Neuroscience Research Unit, Health Science Campus, Taif University, P.O. Box 11099, 21944 Taif, Saudi Arabia. |
| المصدر: | Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy [Spectrochim Acta A Mol Biomol Spectrosc] 2024 Jul 05; Vol. 315, pp. 124245. Date of Electronic Publication: 2024 Apr 02. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: England NLM ID: 9602533 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-3557 (Electronic) Linking ISSN: 13861425 NLM ISO Abbreviation: Spectrochim Acta A Mol Biomol Spectrosc Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Original Publication: [Kidlington, Oxford, U.K. ; Tarrytown, NY] : Pergamon, c1994- |
| مواضيع طبية MeSH: | Valine*/*analogs & derivatives, Imidazoles*/pharmacokinetics , Imidazoles*/chemistry , Valine*/pharmacokinetics , Simeprevir*/pharmacokinetics , Simeprevir*/analysis , Pyrrolidines*/chemistry , Carbamates*/pharmacokinetics , Spectrometry, Fluorescence*/methods, Least-Squares Analysis ; Algorithms ; Antiviral Agents/pharmacokinetics ; Reproducibility of Results |
| مستخلص: | Simeprevir and daclatasvir represent a cornerstone in the management of Hepatitis C Virus infection, a global health concern that affects millions of people worldwide. In this study, we propose a synergistic approach combining synchronous spectrofluorimetry and chemometric modeling i.e. Partial Least Squares (PLS-1) for the analysis of simeprevir and daclatasvir in different matrices. Moreover, the study employs firefly algorithms to further optimize the chemometric models via selecting the most informative features thus improving the accuracy and robustness of the calibration models. The firefly algorithm was able to reduce the number of selected wavelengths to 47-44% for simeprevir and daclatasvir, respectively offering a fast and sensitive technique for the determination of simeprevir and daclatasvir. Validation results underscore the models' effectiveness, as evidenced by recovery rates close to 100% with relative root mean square error of prediction (RRMSEP) of 2.253 and 2.1381 for simeprevir and daclatasvir, respectively. Moreover, the proposed models have been applied to determine the pharmacokinetics of simeprevir and daclatasvir, providing valuable insights into their distribution and elimination patterns. Overall, the study demonstrates the effectiveness of synchronous spectrofluorimetry coupled with multivariate calibration optimized by firefly algorithms in accurately determining and quantifying simeprevir and daclatasvir in HCV antiviral treatment, offering potential applications in pharmaceutical formulation analysis and pharmacokinetic studies for these drugs. Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (Copyright © 2024 Elsevier B.V. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Daclatasvir; Firefly algorithm; HCV; PLS; Pharmacokinetics; Simeprevir |
| المشرفين على المادة: | LI2427F9CI (daclatasvir) 0 (Imidazoles) HG18B9YRS7 (Valine) 9WS5RD66HZ (Simeprevir) 0 (Pyrrolidines) 0 (Carbamates) 0 (Antiviral Agents) |
| تواريخ الأحداث: | Date Created: 20240406 Date Completed: 20240504 Latest Revision: 20240504 |
| رمز التحديث: | 20240505 |
| DOI: | 10.1016/j.saa.2024.124245 |
| PMID: | 38581722 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1873-3557 |
|---|---|
| DOI: | 10.1016/j.saa.2024.124245 |